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ABSTRACT 
The peroxisome proliferator-activated receptors (PPARs) are members of the 
nuclear hormone receptor superfamily of transcription factor that mediate ligand-
dependent transcriptional activation and repression. They regulate genes associated 
with lipid and glucose metabolism. Recent evidence suggests that PPARs may also 
act as a negative immunomodulator. To investigate the potential role of PPARa, y1 
and y2 in regulating inflammation mediated by monocyte, the expression of PPARa, 
y1 and y2 in lipopolysaccharide (LPS)-activated and non-activated human monocytes 
was quantified. 
Monocytes secrete inflammatory cytokines such as interleukin (IL)-1 ~' IL-6 and 
tumor necrosis factor (TNF)-a in response to LPS. To verify stimulation of monocytes 
by LPS, various cytokines including granulocyte/macrophage colony-stimulating 
factor (GM-CSF), TN F-a, IL-1 ~' IL-6, IL-8 and transforming growth factor (TGF)-
J3 expression of LPS-activated and non-activated human monocytes was analyzed by 
using multiplex PCR and their expression is normalized against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression. All these inflammatory cytokine 
expressions were increased in LPS-activated monocytes compared to non-activated 
monocytes. 
Measurement of the gene expression levels of PPARa, PPARy1 and PPARy2 
in both LPS-activated and non-activated monocytes was carried out using Real-Time 
PCR analysis. The study showed that LPS induced expression of both PPARa and 
PPARy2 in isolated human monocytes with a preferential upregulation of PPARy2. 
The PPARy1 however was not expressed in both LPS-activated and non-activated 
monocytes. The activation of PPARa. and PPARy2 by LPS indicates that they may 
play a role in the down-regulation of immune response evoked by LPS. In contrast, 
PPARy1 may not be involved in normal functional of monocytes nor participate in 
modulating immune response induced by LPS. Human monocytes express PPARa. 
as well as PPARy2 with the amount of PPARy2 lower compared to PPARa.. 
2 
INTRODUCTION 
Peroxisome proliferator-activated receptors (PPARs) are transcription factors 
belonging to the nuclear receptor superfamily. Three human PPAR isoforms have 
been identified to date: PPARa, 8/(3 and y (Vamecq and Latruffe, 1999; Rosen and 
Spiegelman, 2001; Tedgui and Mallat, 2001). PPARy has three splice variants termed 
PPARy1, y2 and y3 (Willson eta/., 2001; Kintscher eta/., 2002). 
Like other members of the steroid-receptor superfamily, PPARs have five 
structural regions (A-E) with four functional domains as shown in figure 1. The N-
terminal or A/8 domain encodes the transcriptional activation function 1 (AF1) 
domain, which contains a mitogen-activated protein kinase (MAPK) phosphorylation 
site. Phosphorylation at this site reduces the transcriptional activity of PPAR by 
reducing its ability to bind ligands (Willson eta/., 2001 ). The C domain is the DNA-
binding domain (DBD). The D domain consists of a highly flexible hinge region 
(Boitier et a/., 2003). The E domain is the ligand-binding domain (LBO) which 
contains the activation function 2 (AF2) ligand-dependent activation domain (Vamecq 
and Latruffe, 1999; Boitier eta/., 2003). In addition, the E region is also important in 
nuclear localization and dimerization of the receptor. The three PPARs share 80o/o 
and 70°/o amino acid identity in their DBDs and LBDs, respectively as indicated in 
figure 2 (Willson et at 2001 ). 
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Figure 1. A schematic illustration of the domain structure of PPARs (Boitier eta/. , 2003). 
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PPARs heterodimerize with the retinoid X receptor (RXR) (Figure 2). In the 
unliganded state, evidence indicates that the PPARs are associated with a nuclear 
receptor co-repressor. Upon activation by ligands for either PPAR or RXR, the 
PPARs undergo a conformational change that results in the dissociation from the co-
repressor, enabling the PPAR to bind nuclear receptor co-activators and subsequent 
binding to specific peroxisome proliferator-responsive elements {PPRE), a direct 
repeat of the consensus sequence, AGGTCA, separated by a single nucleotide 
spacer, a so-called DR-1 motif located within the promoter region of target genes. 
(Chinetti eta/., 1998; Knethen and Brune, 2001; Neve eta/., 2001: Tedgui and Mallat, 
2001; Wang eta/., 2001). These co-activators then act to reorganize the chromatin 
templates allowing the basal transcription machinery to gain access to the promoter 
regions driving transcription or repression of target genes (Jones eta/., 2002). 
Fatty acid derivatives and eicosanoids have been identified as natural ligands 
for PPARs. Furthermore, fibrates are synthetic ligands for PPARa. that mediate the 
lipid-lowering activity of these drugs, whereas the antidiabetic thiazolidinediones and 
carbaprostacyclin are synthetic ligands for PPARy and PPARo, respectively (Chinetti 
eta/., 1998; Delerive eta/., 1999; Tedgui and Mallat 2001). 
Neve et a/., {2001) reported that human monocytes and macrophages express 
PPARa as well as PPARy, although the amount of PPARy compared with PPARa 
may be lower in these cells. In monocytes, expression of PPARa and PPARy 
increases during differentiation (Chinetti et a/., 1998; Marx et a/., 2001: Neve et a/., 
2001; Cunard eta/., 2002). 
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Figure 2. PPAR isoforms share a common domain structure and molecular mechanism of 
action. Amino acid numbers are indicated above each receptor, whereas percent identity at 
the amino acid level with PPAR8 is displayed within each domain. In the lower half of the 
panel, a generic PPAR is shown binding to a PPRE as a heterodimer with RXR (Rosen and 
Spiegelman, 2001 ). 
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According to Wright et a/., (1990) and Maliszewski (1991 ), leukocytes 
including monocytes respond to lipopolysaccharide (LPS) at nanogram per milliliter 
concentrations with secretion of cytokines such as IL-1 f3, IL-6 and TN Fa. LPS in the 
bloodstream rapidly binds to the serum protein, lipopolysaccharide binding protein 
(LBP) (Schumann eta/., 1990; Wright eta/., 1990). CD14, a differentiation antigen of 
monocytes and macrophages, then binds complexes of LPS and LBP (Wright eta/., 
1990; Bazil and Strominger, 1991; Maliszewski, 1991 ). However, Wright eta/., (1990) 
reported that LPS in the concentration used (1 OOng/ml) can activate monocytes in the 
absence of either LBP or CD14. 
PPARs have been shown to down-regulate inflammatory response (Jozkowicz 
et a/., 2000; Cunard et a/., 2002). PPARa. activation negatively regulates 
cyclooxygenase type 2 (COX-2) activity (Vamecq and Latruffe, 1999), whereas 
PPARy reduces monocyte secretion of inflammatory cytokines (Jiang et a/., 1998; 
Vamecq and Latruffe, 1999; Kersten eta/., 2000). 
Little is known, however, about the induction of expression of different 
isoforms of PPARs in monocyte/macrophages upon activation by LPS. To get an 
initial insight into this question, the effects of LPS stimulation on PPARa, y1 and y2 
expression in freshly isolated human monocytes were investigated. Activation of 
monocytes by LPS was verified through comparison of inflammatory cytokines 
expression in both LPS-activated and non-activated monocytes. Absolute 
quantification of PPARa, y1 and y2 expression was measured using Real time PCR. 
7 
REVIEW OF LITERATURE 
In 2001, Hsueh and Law showed that high doses ofthiazolidinediones (TZD's), 
which are ligands for the PPARy, reduced monocyte adhesion to endothelial cells in 
vitro, as well as inflammatory actions of macrophages, including their expression of 
IL-1, IL-6, TNFa, inducible nitric oxide synthethase (iNOS), and chemokine (C-C motif) 
receptor-2 (CCR-2). These data suggest that PPARy ligands may attenuate 
inflammation and hence, atherosclerosis in the vessel wall (Hsueh and Law, 2001 ). 
In 1999, Leininger et a/. reported that induction of PPARy coincided with or 
closely followed an endotoxin challenge and host responses to acute inflammation in 
peripheral porcine blood monocytes. However, Jiang et a/. (1998) presented 
evidence that the inflammatory cytokine TN F-a which is rapidly produced by 
monocytes and macrophages in response to a number of stimuli such as endotoxins 
antagonizes the synthesis of PPARy. 
In the same year, Ricote et a/. provided evidence that oxidized low density 
lipoprotein ( oxLDL), macrophage colony-stimulating factor (M-CSF), and 
granulocyte/macrophage colony-stimulating factor (GM-CSF) which are known to be 
present in atherosclerotic lesions, stimulated PPARy expression in primary 
macrophages and monocytic cell lines. PPARy expression was detected in the 
adherent macrophage population that was induced by M-CSF. GM-CSF also induced 
PPARy mRNA expression in the adherent macrophage population, although less 
strongly than M-CSF. Treatment of resident peritoneal macrophages with M-CSF and 
GM-CSF led to a marked increase in PPARy protein levels. In contrast, treatment of 
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resident peritoneal macrophages with interferon (IFN)-y or LPS did not stimulate 
PPARy expression. 
Recently, however, Knethen and BrUne (2001) provided evidence that the 
classic macrophage stimulators LPSIIFN-y promote PPARy activation. This is 
established by gel shift analysis, a supershift response in the presence of PPARy but 
not PPARa antibodies, and a reporter gene assay coupled to luciferase activity. 
Activation of PPARy was analyzed by electrophoretic mobility shift assays (EMSA) 
using a specific PPRE oligonucleotide derived from the human acyi-CoA synthase 
promoter. They proposed that LPS/IFN-y induce a PPARy response via production of 
activating ligands, which awaits further characterization. Thus, LPS/IFN-y had been 
implicated in PPARy activation in macrophages. But, there is still unclear whether the 
3 PPARy splice variants- PPARy1, y2 and y3 are evenly expressed upon monocyte 
activation by LPS/IFN-y. 
In 2002, Kintscher et a/. demonstrated that TGF-J31, an essential and potent 
immune modulator induces transcriptionally active PPARy1 and y2 in THP-1 
monocytes, a human monocytic leukemia cell line with a preferential up-regulation of 
PPARy2. TGF-f31 strongly induced PPARy2 mRNA and protein expression with a 
lesser effect on PPARy1. Transcription from a PPARy2 promoter/luciferase reporter 
vector was activated approximately 3-fold by TGF-J31. They also showed that 
mutation of two C/EBP recognition elements, a regulator of PPARy2 promoter that is 
situated within the PPARy2 promoter at -340 and -327 bp relative to the transcription 
start site reduced TGF-J31-induced transcription by approximately 65°/o. 
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Few studies were done on PPARa. as compared to PPARy. In 1998, Poynter 
and Daynes reported that the nuclear factor (NF)-KB-driven cytokines- TN F-a., IL-1 f3, 
and IL-6 cause a reduction in the expression of PPARa.. On the other hand, Neve et 
at. (2001) reported that LPS had no effect on the level of PPARa. protein expression 
in monocytic leukemia THP-1 cells. 
To date, there is still no report on the expression of PPARa. in LPS-stimulated 
isolated human monocytes. Moreover, it is uncertain whether monocytes would 
differentially express the different isoforms of PPARs (PPARa., y1 and y2) upon 
stimulation by LPS. 
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OBJECTIVE OF THE STUDY 
The objectives of this study are to: 
1. Quantify PPARa, PPARy1 and PPARy2 expression in LPS-activated and non-
activated human monocytes by Real-Time PCR. 
2. Compare PPARa, PPARy1 and PPARy2 expression in LPS-activated human 
monocytes with their corresponding expression in non-activated human 
monocytes. 
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MATERIALS AND METHODS 
SUMMARY OF EXPERIMENTAL PROTOCOL 
Peripheral blood collection in EDTA tube 
Flow cytometry analysis 
Isolation of monocytes by adherence 
Adherent monocytes Non-adherent monocytes 
Flow cytometry analysis 
Total RNA extraction 
Quantificat ion & determination of quality of total RNA 
Multiplex PCR (Human 
inflammatory cytokine genes) 
PCR (H uman, 188 rRNA) 
Real-time PCR (PPARa., PPARy1 & 
PPARy2) 
Figure 3. Flow chart of experimental protocol. 
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MATERIALS 
Human Venous Blood Samples 
Five healthy humans (3 females and 2 males) venous blood samples were collected 
for this experiment. 
Reagents 
Ficoll Histopaque-1 077 (P=1.077 ± 0.001 g mr1) (Sigma, USA), LPSs (Sigma, 
Germany), human monoclonal antibodies- lgG1 FITC, lgG1 PE, anti-CD3 FITC, anti-
CD4 PE, anti-COB PE and anti-CD14 PE (Becton Dickinson, USA), RNeasy RNA 
Extraction Kit (Qiagen, USA), RevertAid™ H Minus First Strand eDNA Synthesis Kit 
(Maxim Bio, USA), PCR set kit for human 18S rRNA (Maxim Bio, USA), 100 bp 
molecular weight marker (Invitrogen, USA), 6x loading buffer (Fermentas, USA), 100 
bp DNA marker (Fermentas, USA), and MPCR kit for human inflammatory genes set 
1 (Maxim Bio, USA). 
Chemicals 
Ethanol (Merck, Germany), ethylene diamine tetra acetic acid (EDTA) (Sigma, USA), 
NaH2P04.2H20 (E. Merck, Germany), KCI (BDH Lab, UK), NaCI (E. Merck, 
Germany), NH4CI (BDH, England), KHCO (BDH, England), Trypan blue (Sigma, 
USA), Dulbecco's Modified Eagle's Medium (DMEM) powder (Sigma, USA), sodium 
bicarbonate solution (7.5°/ow/v) (Sigma, USA), Tris base (Promega, USA), diethyl 
pyrocarbonate (DEPC) water (Sigma, USA), orange G (Sigma, USA), ethidium 
bromide (EtBr) powder (Sigma,USA), agarose powder (Promega, USA), and boric 
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acid (Promega, USA). All chemicals were of the highest grade of purity and 
commercially available. 
Equipments 
Haemacytometer (Assistant, Germany), light microscope (Leica Microsystems, 
Germany), 25-cm2 cell culture flasks (Costar, USA), C02-water jacketed incubator 
(Nuaire, USA), 5 ml polystyrene round-bottom tube (Becton Dickinson, USA), 
FACScan flow cytometer (Becton Dickinson, USA), spectrophotometer (Eppendorf, 
Germany), RNase-free quartz cuvette {Eppendorf, Germany), agarose gel apparatus 
model MGU-202T (C.B.S. Scientific Co., California), electrophoresis power supply 
(Amersham Pharmacia Biotech, USA), UV transilluminator (Spectroline, Model TC-
312A, USA), digital image analyzer (Amersham Pharmacia Biotech, USA), mini 
centrifuge (National Labnet Co., Woodbridge), Perkin Elmer GeneAmp PCR system 
2400 (Applied Biosystems, USA), lmageMaster Totallab software (Amersham 
Pharmacia Biotech, USA), Perkin Elmer GeneAmp PCR system 9700 (Applied 
Biosystems, USA), ABI PRISM® 5700 Sequence Detector (Applied Biosystems, 
USA), and Primer Express software (Applied Biosystems, USA). 
Statistical Analysis 
Each experiment was performed at least five times and statistical analysis was 
performed using the two tailed Student's t-test using the SPSS software version 11.0 
(SPSS Science Inc., USA). 
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GENERAL REAGENTS PREPARATION 
a) 70o/o ethanol solution 
To prepare 70o/o ethanol solution, 70 ml ethanol was mixed with 30 ml 
deionized water. 
b) 0.5 M EDTA pH 8.0 
A 0.5 M EDTA solution was prepared by dissolving 93.06 g EDTA in 300 ml 
deionized water. The pH of the solution was adjusted to 8.0 since EDTA would only 
dissolve at pH 8.0. When EDTA was completely dissolved, the final volume was 
made up to 500 ml by adding deionized water. 
MEDIA PREPARATION 
a) 1 Ox phosphate-buffered saline (PBS) 
In preparing 1 Ox PBS stock solution, 1.4 g NaH2P04.2H20, 0.2 g KCI and 8.1 
g NaCI were dissolved in 800 ml deionized water and the pH of the solution was 
adjusted to 7.4 using 3 M NaOH. The solution was then made up to 1 L by adding 
deionized water. The final stock solution was autoclaved at 121 oc for 15 minutes and 
stored at room temperature. To prepare 1 x PBS working solution, the 1 Ox PBS stock 
solution was further diluted by adding deionized water. This working solution was 
stored at 4°C. 
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b) Lysis buffer, 6x ammonium chloride solution (ACK) 
A 6x ACK lysis buffer was prepared by dissolving 49.7 g NH4CI, 100.1 g 
KHCO and 0.222 g EDTA in 800 ml deionized water and the pH of the solution 
adjusted to 7.4 by 3 M NaOH. The solution then was made up to 1 L by adding 
deionized water. To prepare a working solution, the 6 X ACK stock solution was 
diluted by deionized water and the 1 X ACK was filtered through a 0.2 J.lm pore 
membrane filter for sterilization. 
c) Dulbecco's Modified Eagle's Medium (DMEM) 
DMEM (containing 4 mM L-glutamine) was prepared by dissolving 10 g DMEM 
powder in 800 ml deionized water. For each liter of medium, 49.3 ml of sodium 
bicarbonate solution (7.5°/ow/v) was added. The pH of the medium was adjusted to 
7.0 by using 1 N HCI or 1 N NaOH. Then additional deionized water was added to 
bring the solution to the final volume. DMEM (containing 2 mM L-glutamine) was 
used for culturing human monocytes by the addition of an equal volume of deionized 
water. To bring to a concentration of 50 J.t9 gentamycin/ml DMEM, 0.1 g of 
gentamycin powder was added to DMEM. This medium was then filtered through 0.2 
J.tm pore membrane filter and stored at 4°C. 
d) LPS stock solution preparation 
Lyophilized LPS was reconstituted with 1 ml sterile Hank's Balanced Salt 
Solution (HBSS) and further diluted to the working concentration of 10 ng/ml DMEM 
using HBSS (Bazil and Strominger (1991)) and stored at -20°C. 
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PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC) ISOLATION 
Twenty ml venous blood from healthy donors was collected into tubes 
containing EDTA. Experiments were initiated on the day blood was collected and all 
manipulations were carried out under sterile conditions. PBMC was isolated by 
density gradient centrifugation. The blood was diluted 1 :2 with PBS in four 15 ml 
Falcon tubes and layered slowly onto a 3 ml Ficoll Histopaque-1 077 (P=1.077 ± 
0.001 g mr1) per 10 ml blood by using a sterile Pasteur pipette. The preparation was 
then centrifuged at 1500 rpm (400 x g) for 30 min. The interphase containing 
peripheral blood mononuclear cells was obtained after centrifugation. 
The mononuclear cell layer was transferred to a fresh tube, mixed with 3 
volumes PBS and centrifuged for 5 min at 1500 rpm. The supernatant was removed 
and if the cell pellet is contaminated with red blood cells, 1 ml ACK was added to the 
pellet and mixed well to lyse red blood cells for 5 min at room temperature. After 5 
min, the cell suspension was centrifuged at 1500 rpm for 5 min. After centrifugation, 
the supernatant was removed and the cell pellet washed with 10 ml PBS and the cell 
suspension centrifuged again at 1500 rpm (400 x g) for 5 min. Mononuclear cells 
were resuspended in 1 ml PBS and counted by using haemacytometer under light 
microscopy. Before counting, 5 ~I cell suspension was mixed with 5 ~I 0.2°/o Trypan 
blue. Flow cytometry analysis was carried out on this cells suspension to determine 
the percentage of monocytes in PBMC. 
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ISOLATION OF MONOCYTES BY ADHERENCE AND LPS ACTIVATION 
Monocytes were isolated from mononuclear cells by exploiting their ability to 
adhere to glass or plastic. PBMC was suspended in serum-free DMEM which is 
supplemented with 2 mM L-glutamine and 50 Jlg/ml gentamycin at 2 x 106 cells/mi. 
Five ml of the cell suspension was added to two 25-cm2 cell culture flasks and 
incubated for 1 hour in a humidified 37°C, 5°/o C02 incubator. 
After 1 hour, the non-adherent cells were decanted into two 15 ml Falcon 
tubes and counted by using haemacytometer after adding 0.2% Trypan blue in 1 :2 
dilution. Flow cytometry analysis was performed on these cell suspensions to 
estimate the percentage of monocytes that have adhered to the flasks. The cell 
culture flasks were washed twice with 5 ml serum-free DMEM to remove any residual 
non-adherent cells and 5 ml fresh DMEM was replaced into each flask. 
To induce activation of monocytes, 10 ng/ml LPS was added into one of the 
flasks and the other used as the control. The flasks were incubated for 7 days in a 
humidified 37°C, So/o C02 incubator. 
FLOW CYTOMETRY 
Flow cytometry analysis was carried out using monoclonal antibodies labeled 
with fluorescent dyes specific for mononuclear cells (Th cells, Tc cells and monocytes) 
surface antigens. Fluorescein isothiocyanate (FITC) and phycoerythrin (PE) labeled 
monoclonal antibodies which emit green and orange fluorescence respectively were 
used. 
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A total of 10 J.ll antibodies conjugated with FITC or PE was added into each 5 
ml polystyrene round-bottom tube as shown in table 1. Fifty J.ll total PBMC or 100 J.tl 
non-adherent PBMC was added into each tube, mixed well and placed in the dark for 
30 minutes. All 4 tubes were centrifuged at 1500 rpm (400 x g) for 5 minutes. After 
centrifugation, supernatants were removed and 2 ml PBS was added into each tube 
and centrifugation step was repeated. The cells were fixed and analyzed by using 
F ACScan flow cytometer. 
TOTAL RNA EXTRACTION 
After the 7-day incubation period, total RNA was extracted from both activated 
and non-activated monocytes by using the RNeasy RNA Extraction Kit. The 
monocytes were disrupted directly by addition of 350 J.ll Buffer RLT with ~­
mercaptoethanol (J3-ME) (1 0 J.tl J3-ME per 1 ml Buffer RL T) after completely removing 
the cell culture medium. The lysate was then transferred onto a QIAshredder spin 
column placed in a 2 ml collection tube and centrifuged for 2 min at maximum speed 
(12,000 rpm) to homogenize the sample. One volume (350 J.tl) of 70°/o ethanol was 
added to the homogenized lysate and mixed well by pipetting. 
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Tube FITC PE Purpose 
1 lg G1 lg G1 As control to set 
marker. 
2 CD3 CD4 To determine the 
percentage of Th 
cells. 
3 CD3 CDS To determine the 
percentage of Tc 
cells. 
4 CD14 To determine the 
percentage of 
monocytes. 
Table 1. Human monoclonal antibodies employed in flow cytometry analysis. 
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The sample was then applied to an RNeasy mini column placed in a 2 ml 
collection tube and centrifuged for 15 s at 10,000 rpm. The flow-through was 
discarded and 700 J!l Buffer RW1 was added to the RNeasy column and centrifuged 
for 15 s at 10,000 rpm to wash the column. The flow-through together with collection 
tube was discarded. The column was then transferred into a new 2 ml collection tube 
and washed by pipetting 500 J.tl Buffer RPE with 4 volumes of 1 00°/o ethanol and 
centrifuged for 15 s at 10,000 rpm. The flow-through was discarded and another 500 
!JI Buffer RPE was added to the RNeasy silica-gel membrane but was centrifuged at 
10,000 rpm for 2 min to dry the membrane. To eliminate any chance of possible 
Buffer RPE carryover, the column was placed in a new 2 ml collection tube and was 
centrifuged at full speed for 1 min. Finally, to elute the RNA into a 1.5 ml collection 
tube, 20 J!l RNase-free water was pipetted directly onto the RNeasy silica-gel 
membrane and centrifuged for 1 min at 10,000 rpm. Purified RNA was stored at -
40°C. 
QUANTIFICATION AND DETERMINATION OF QUALITY OF TOTAL RNA 
Quantification of RNA 
The concentration of the RNA was determined by measuring the absorbance 
at 260 nm (A260) in a spectrophotometer. An absorbance of 1 unit at 260 nm 
corresponds to 40 J!g of RNA per mi. This relation is valid only for measurements in 
water. Therefore, RNA sample was diluted by using RNase-free water (1 !JI RNA in 
49 !JI RNase-free water) in an RNase-free quartz cuvette. 
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Purity of RNA 
The purity of the samples was then checked to determine if the RNA samples 
had been contaminated by DNA or protein. Proteins absorb light at 280nm, and DNA 
absorbs more weakly than RNA, so to find relative sample purity, the ratio of the 
readings at 260 nm and 280 nm (A2eo/A2ao) was determined. Pure RNA has an 
A2so/A2ao ratio of 1.8-2.1 in RNase-free water. However, if protein or DNA, or both are 
present in the sample, then the value of the ratio will drop to about 1 or lower. If the 
impurities were acceptably small the RNA could be used in the next steps. 
Integrity of RNA 
Agarose gel electrophoresis reagents preparation 
a) 50x Tris-acetate buffer (T AE) 
A sox TAE buffer for RNA product analysis was prepared by dissolving 121 g 
Tris base, 28.5 ml glacial acetic acid and 50 ml 0.5 M EDTA pH 8.0 in DEPC water in 
a final volume of 500 mi. The buffer was autoclaved at 121 oc for 15 min for 
sterilization. By diluting 50x TAE buffer with DEPC water, 1 x TAE running buffer and 
gel loading buffer can be prepared. The stock as well as working solution was stored 
at room temperature. 
b) RNA loading buffer 
RNA loading buffer was prepared by dissolving 20 g sucrose and 0.125 g 
orange G in 50 ml OEPC water. This buffer was stored at 4°C. 
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c) Ethidium bromide (EtBr) solution 
To prepare 10 mg/ml stock EtBr solution, 0.1 g EtBr powder was dissolved in 
1 0 ml deionized water and stored in a dark or foil-wrapped bottle at room temperature. 
Agarose gel electrophoresis 
The integrity and size distribution of total RNA can be checked by agarose gel 
electrophoresis and EtBr staining. The respective ribosomal bands (285 rRNA and 
185 rRNA) should appear as sharp bands on the stained gel with 285 rRNA bands 
present with an intensity approximately twice that of the 188 rRNA. If the ribosomal 
bands are not sharp. but appear as a smear of smaller sized RNAs. it is likely that the 
RNA sample suffered major degradation during preparation. 
The percentage of agarose gel being used was 1 °/o. To prepare 1 °/o agarose 
gel, 0.3 g agarose powder was dissolved in 30 ml 1 x TAE buffer and boiled in a 
microwave oven. The gel solution was then cooled to 55°C in the water bath and 1 )ll 
10 mg/ml EtBr was added to the gel solution. The agarose solution was poured onto 
an appropriate gel tray that had been assembled with a comb and allowed to harden 
at room temperature for 20-30 min. 
Agarose gel electrophoresis was run at 85 V for 1 h. One )ll RNA loading 
buffer was mixed with 5 Jll total RNA and the sample was loaded into the wells of the 
gel. UV transilluminator was used to visualize RNA in the gel. EtBr molecule 
intercalates RNA and causes RNA to fluoresce upon exposure of the bound RNA to 
UV light. The image of the RNA bands was then captured by using a digital image 
analyzer. 
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SYNTHESIS OF FIRST STRAND eDNA 
RevertAid™ H Minus First Strand eDNA Synthesis Kit was used to synthesize 
full-length first strand eDNA from RNA templates. One Jlg total RNA was used for 
each synthesis. Oligo (dT)1a primer (0.5 J.tg/J.tl) was selected as the primer in this 
reaction so that only mRNAs with 3'-poly(A) tails served as templates for eDNA 
synthesis since this primer is complementary to the 3'-end of poly(At mRNA. The 
reaction mixture which is composed of 1 Jlg total RNA, 1 J.tl Oligo (dT)1a primer (0.5 
JlgiJ.tl) and nuclease free deionized water was prepared in a sterile microcentrifuge 
tube on ice to bring the volume to 12 Jll. 
Before incubating the mixture at 7ooc for 5 min. the mixture was mixed gently 
and centrifuged briefly in a mini centrifuge. The mixture was then chilled on ice, 
centrifuged briefly and 4 Jll 5x reaction buffer, 1 J.tl ribonuclease inhibitor (20u/J.tl) and 
2 Jll 1 OmM dNTP mix were added to the mixture. The tube was mixed gently and 
centrifuged briefly before incubating at 37°C for 5 min. Finally, 1 J.tl RevertAid™ H 
Minus M-MuLV Reverse Transcriptase (200u/J.tl) was added to bring the final volume 
to 20 Jll. The mixture was incubated at 42°C for 60 min and the reaction was stopped 
by heating at 70°C for 10 min. The eDNA produced was chilled on ice and diluted to 
100 Jll by adding RNase-free water. The eDNA sample was assigned into two 
aliquots before storing at -40°C for later use. 
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